Nachman, S., Alvero, C., Acosta, E. P., Teppler, H., Homony, B., Graham, B., . . . Wiznia, A. (2015). Pharmacokinetics and 48-Week Safety and Efficacy of Raltegravir for Oral Suspension in Human Immunodeficiency Virus Type-1-Infected Children 4 Weeks to 2 Years of Age. J Pediatric Infect Dis Soc.
Chicago Style CitationNachman, Sharon, et al. "Pharmacokinetics and 48-Week Safety and Efficacy of Raltegravir for Oral Suspension in Human Immunodeficiency Virus Type-1-Infected Children 4 Weeks to 2 Years of Age." J Pediatric Infect Dis Soc 2015.
Cita MLANachman, Sharon, et al. "Pharmacokinetics and 48-Week Safety and Efficacy of Raltegravir for Oral Suspension in Human Immunodeficiency Virus Type-1-Infected Children 4 Weeks to 2 Years of Age." J Pediatric Infect Dis Soc 2015.